Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks

In this article, we discuss the 5 stocks receiving price-target cut from analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks.

05. FedEx Corporation (NYSE:FDX)

Price Reaction after the Price Target Cut: -4.84 (-1.73%)

On April 2, BofA Securities analyst Ken Hoexter revised down the price target for FedEx Corporation (NYSE:FDX) from $346.00 to $340.00, despite retaining a Buy rating for the company. FedEx Corporation (NYSE:FDX) operates in the logistics and delivery services sector, facilitating global shipping and transportation solutions. FedEx exceeded expectations in the third quarter, with an adjusted EPS increase of 13% year-over-year, surpassing both the target set by Bank of America Securities and the consensus estimate. The company remains on course with its cost-saving initiatives, particularly the DRIVE program, which is anticipated to deliver $1.8 billion in savings in fiscal 2024, with an additional $4.2 billion planned for subsequent years. These savings are forecasted to significantly bolster FedEx Corporation (NYSE:FDX) EPS, indicating strong potential for profitability growth. Moreover, further supporting the Buy rating, FedEx has demonstrated effective cost management strategies, including notable reductions in incentive compensation, which contributed to the earnings beat for the quarter. Despite the short-term negative market response, the Buy rating by Ken Hoexter implies confidence in FedEx Corporation (NYSE:FDX) long-term growth potential.

Artisan Value Fund stated the following regarding FedEx Corporation (NYSE:FDX) in its fourth quarter 2023 investor letter:

“Other Q4 laggards were global reinsurer Arch Capital and shipping company FedEx Corporation (NYSE:FDX)—holdings that pulled back following large gains. Back in September 2022, FedEx was selling for less than 8X our estimate of normalized earnings due to substantial pessimism. Although the demand environment remains challenging globally, particularly in the Express segment, the company is delivering solid earnings growth driven by cost savings initiatives. FedEx’s DRIVE program, which seeks to deliver $4 billion in permanent cost reductions by creating an integrated air-ground network similar to that of rival UPS, is showing progress, and workforce reductions have also been enacted. While operating results can be choppy, FedEx’s longer term business economics are highly favorable given the global shipping industry’s consolidated structure and massive barriers to entry that afford operators with pricing power to counter cost inflation and earn respectable returns on capital over the business cycle.”

04. General Electric Company (NYSE:GE)

Price Reaction after the Price Target Cut: -3.38 (-2.42%)

On April 2, JPMorgan Chase & Co. revised its target price for General Electric Company (NYSE:GE) downward from $180.00 to $148.00, while maintaining an “overweight” rating on the stock. General Electric Company (NYSE:GE) operates in the industrial conglomerates sector, providing a diverse range of products and services across various industries. On January 23, General Electric Company (NYSE:GE) last released its earnings. The conglomerate reported earnings per share of $1.03 for the quarter, surpassing the consensus estimate of $0.90 by $0.13. Revenue for the quarter stood at $19.42 billion, exceeding analysts’ expectations of $17.27 billion. General Electric Company (NYSE:GE) achieved a return on equity of 10.88% and a net margin of 13.95%. Quarterly revenue witnessed a 15.4% increase compared to the same quarter the previous year. In the corresponding quarter of the prior year, the company had earned $1.24 earnings per share. Market reacted negatively to the decision of price target cut by JPMorgan Chase & Co. as the stock fell by 2.42% on the closing bell on April 2. Despite this short-term market response, the “overweight” rating implies confidence in General Electric Company (NYSE:GE) long-term growth prospects. JPMorgan’s decision to maintain an optimistic view on General Electric Company (NYSE:GE) underscores its belief in the company’s ability to overcome challenges and capitalize on opportunities in the industrial sector.

03. Tesla, Inc. (NASDAQ:TSLA)

Price Reaction after the Price Target Cut: -8.59 (-4.90%)

On April 2, Baird analysts adjusted their price target for Tesla, Inc. (NASDAQ:TSLA) downward from $300 to $280, while maintaining an outperform rating on the shares. Tesla, Inc. (NASDAQ:TSLA) operates in the electric vehicle (EV) industry, pioneering advancements in sustainable transportation and energy solutions. Baird’s decision to lower the price target indicates a reassessment of Tesla, Inc. (NASDAQ:TSLA) valuation, taking into account recent developments and market trends. The market reacted negatively to the news as evident from the 4.90% price drop following the price target cut. Despite this short-term negative market response, the outperform rating implies confidence in Tesla, Inc. (NASDAQ:TSLA) long-term growth potential. Baird’s rationale for the price target adjustment highlights Tesla, Inc. (NASDAQ:TSLA) first-quarter deliveries, which fell below estimates. The company cited several one-time factors impacting production, contributing to the lower-than-expected results. While the price target revision may influence near-term sentiment, the outperform rating suggests Baird sees intrinsic value in Tesla, Inc. (NASDAQ:TSLA) innovative approach and its potential to shape the future of transportation.

02. Disc Medicine, Inc. (NASDAQ:IRON)

Price Reaction after the Price Target Cut: -2.17 (-6.36%)

On April 2, Morgan Stanley analyst Jeffrey Hung revised down the price target for Disc Medicine, Inc. (NASDAQ:IRON) from $75.00 to $40.00, all while retaining an Equal Weight rating on the company’s shares. Disc Medicine, Inc. (NASDAQ:IRON) operates in the biotechnology industry, specializing in the development of novel therapies for hematologic diseases. The  market repsonded negatively to the news as the share price fell by 6.36% on the closing bell on April 2. Despite this short-term market response, the Equal Weight rating implies a balanced view of Disc Medicine, Inc. (NASDAQ:IRON) prospects. Disc Medicine, Inc. (NASDAQ:IRON) released its latest earnings results on March 21. The company reported a loss of $0.97 per share for the quarter, falling short of the consensus estimate of $0.75 by $0.22. While the price target reduction by Morgan Stanley may impact short-term sentiment, the Equal Weight rating suggests Morgan Stanley sees Disc Medicine, Inc. (NASDAQ:IRON) prospects as neither significantly bullish nor bearish, but rather in line with market expectations.

01. Humana Inc. (NYSE:HUM)

Price Reaction after the Price Target Cut: -47.12 (-13.41%)

On April 2, Barclays adjusted the price target for Humana Inc. (NYSE:HUM) downward, reducing it from $356.00 to $310.00, while maintaining an Equal Weight rating for the stock. Humana Inc. (NYSE:HUM) operates in the healthcare sector, specializing in health insurance and related services. The 13.4% decline in price following the reduction in the price target indicates that investors have responded negatively to the news. Despite this significant market response, the Equal Weight rating implies a neutral stance on Humana Inc. (NYSE:HUM) prospects. While the price target reduction may influence short-term sentiment, the Equal Weight rating suggests Barclays sees Humana Inc. (NYSE:HUM) prospects as in line with market expectations.

Diamond Hill Select Strategy stated the following regarding Humana Inc. (NYSE:HUM) in its fourth quarter 2023 investor letter:

“Only one stock detracted from performance in Q4 — health insurance company Humana Inc. (NYSE:HUM). The company faces growing concerns about heightened medical utilization, which would pressure health insurers’ medical loss ratios. Given heightened utilization among the Medicare Advantage population, there is some uncertainty among investors as to whether Humana’s rate bids for 2024 will prove adequate to cover increased costs. However, we maintain our conviction in Humana’s position as a leading insurer catering to the senior population with the opportunity to increase penetration of Medicare Advantage enrollment within the broader Medicare-eligible population.”

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out 10 AI Stocks That Will Skyrocket and 10 Best Silver ETFs To Buy

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.